StockData
Xeris Biopharma Holdings, Inc. logo

Xeris Biopharma Holdings, Inc. (XERS) income statement

XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$16.97+0.35 (+2.11%)

Close on Nov 20, 2026Market cap $3.09BP/E –Yield –

Xeris Biopharma Holdings, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
86.6%
Operating margin
10.9%
Net margin
-5.1%
Return on equity, FY2025
-7.0%

Financial strength

Current ratio
1.45
Debt to equity
-25.95
Debt to assets
61.3%
Cash to current liabilities
64.2%

Valuation

P/E ratio
–
Price to sales
9.22
Price to book
–
Dividend yield
–

See a number that looks wrong?